AMRYT PHARMA (EGFF)
Signed · Ireland, Germany
Source: European Investment Bank (EIB)
This project will finance the research and development (R&D) investment and growth of Amryt Group. Amryt Group is an orphan disease speciality pharmaceutical company which may be characterised by medium to high growth and very high research and development (R&D) intensity. The company is focusing on bringing innovative orphan drugs to the market, addressing clearly identified high unmet medical ne
- Status
- Under Construction
- Sector
- Hospital, Government
- Location
- Ireland
- Updated
- 22 Jul 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about AMRYT PHARMA (EGFF)
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | signed |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | This project will finance the research and development (R&D) investment and growth of Amryt Group. Amryt Group is an orphan disease speciality pharmaceutical company which may be characterised by medium to high growth and very high research and development (R&D) intensity. The company is focusing on bringing innovative orphan drugs to the market, addressing clearly identified high unmet medical needs, and helping increase the quality of life of patients suffering from rare diseases. The R&D intensity of the company is reflected in the active drug development activity and also the fact that it already owns four patent families covering Europe, the US and other major markets (e.g. Japan, Australia, China). |
Original sector | Industry |
Location
Country | Ireland |
Source
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Sector | Hospital, Government |
Article published date | 2025-07-28 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
